Compare Plby Group Inc (PLBY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Zimmer Biomet Holdings Inc — how do they compare? Plby Group Inc trades at $0.98 (market cap $118.21M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 143.4× Plby Group Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PLBY | ZBH | |
|---|---|---|
Market Cap | $118.21M | $16.95B |
Volume | 919,783 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $103.98 |
52-Week Low | $0.99 | $79.58 |
Typical Hold Time | 24 Days | 89 Days |
Enterprise Value | $263.80M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY trades at $0.9867, down 3.26% today, amid bearish technical signals but with improving fundamentals. Recent earnings show a Q2 2026 beat, and cash flow turned positive in 2025. The company is expanding leadership to drive growth, yet faces high debt and negative equity. Analyst consensus is 75% buy, reflecting optimism on turnaround efforts.
Outlook hinges on execution of growth initiatives and debt management. Opportunities include brand licensing expansion and media strategy, but risks from high leverage and competitive pressures persist. Investors should weigh improving operational trends against financial stability concerns.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
